PATENT CLAIM ANALYSIS

Application Number: 16103226
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-02
Patent Classification: ["424", "501000"]

Abstract:
The invention provides compositions comprising microparticles wherein the microparticles comprise at least one adenosine 2 a  receptor antagonist (A2ARA), at least one pharmaceutically acceptable polymer and at least one pharmaceutically acceptable negatively charged agent wherein the microparticles optionally have a highly negative zeta potential of less than about −40 mV. The invention also provides pharmaceutical compositions of the microparticles of the invention and methods of using the compositions of the invention to enhance an immune response in a patient in need thereof and as anti-cancer immunotherapy.

Claim (Index 1):
A composition comprising microparticles wherein the microparticles comprise at least one adenosine 2a receptor antagonist (A2ARA), at least one pharmaceutically acceptable polymer and optionally at least one pharmaceutically acceptable negatively charged agent wherein the microparticles have a negatively charged surface.

Metadata:
- Claim Count in Document: 14.0
- Percentile: 96.0
- Lexical Diversity: 1.59649
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['13878561', '09715902', '15393013', '15808534', '15458560']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6896569007038511
- 35 USC 102 Novelty (BERT): 0.4904646628325588
- Combined Prediction Score: 0.6697376769167219
- Mean Citation Score: 157.144396
- Max Citation Score: 161.34763
- Similarity Product: 100.77954623138548

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test